Possible neural mediation of the central effects of oxytocin on uterine motility.
The central nervous system contains the nuclei at the origin of autonomic and neuroendocrine pathways to the uterus. Although the anatomical basis of these pathways is known, the conditions of their recruitment and their interactions in the context of copulation remain to be explored. We tested the hypothesis that some central mechanisms could simultaneously recruit both pathways to the uterus. In this aim, we recorded intrauterine pressure changes in anesthetized female rats at the estrus stage after intracerebroventricular (ICV) administration of oxytocin (OT). Doses of 0.3-300 ng elicited increases of frequency and amplitude of uterine contractions. These effects were partly mimicked by the OT agonist [Thr(4),Gly(7)]OT but not by arginine vasopressin. They were blocked by the OT receptor antagonist atosiban delivered either ICV or intravenously. The latter suggests that ICV OT activated the systemic release of OT. The effects of OT were also blocked by hexamethonium, a ganglionic blocking agent, by atropine, a muscarinic receptor antagonist, and by N(omega)-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis. The results reveal that ICV OT recruits autonomic efferent pathways to the uterus. These results support our hypothesis that the activation of central nuclei can promote uterine contractility, and that OT may be a central coordinator of autonomic and neuroendocrine pathways. The hypothalamus, the source of direct OT-ergic projections to the pituitary, the brain stem, and the spinal cord, may be a target of central OT.
Benoussaidh
Anissa
A
Analyse & Modélisation en Imagerie Biologique, NOPA-UR-INRA 1197 Bât 325, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas Cedex, France.
Maurin
Yves
Y
Rampin
Olivier
O
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects; D002490:Central Nervous System / Q000502:physiology*; D004525:Efferent Pathways / Q000187:drug effects; D005260:Female; D005730:Ganglionic Blockers / Q000494:pharmacology; D018738:Hexamethonium / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D007276:Injections, Intraventricular; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D010121:Oxytocin / Q000008:administration & dosage / Q000819:agonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015149:Tocolytic Agents / Q000494:pharmacology; D014590:Uterine Contraction / Q000187:drug effects* / Q000502:physiology*; D014668:Vasotocin / Q000031:analogs & derivatives / Q000494:pharmacology
D005730:Ganglionic Blockers; D006727:Hormone Antagonists; D015149:Tocolytic Agents; C047046:atosiban; D018738:Hexamethonium; D010121:Oxytocin; D001285:Atropine; D019331:NG-Nitroarginine Methyl Ester; D014668:Vasotocin